CSE Bulletin: Delist - Canntab Therapeutics Limited (PILL)
Canntab Therapeutics Limited Provides Update on Application for Management Cease Trade Order
Canntab Therapeutics seeks to move manufacturing process as Markham lease expires
Canntab Therapeutics provides update on recent product delivery of its cannabinoid solutions to the Nova Scotia Liquor Corporation
Canntab Therapeutics appoints Hamish Sutherland as strategic business consultant
Canntab Therapeutics inks affiliate deal with independent pharmacy owners in Ontario
Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000
Levitee Labs Teams Up With Canntab Therapeutics, Offer Cannabinoid Products As Alternatives To Opioids
Canntab Therapeutics Completes First Shipment Of THC Tablets To Ontario Cannabis Stores
Levitee Labs partners with Canntab Therapeutics to provide alternative to drugs amid opioid crisis in Canada
Canntab Therapeutics provides an update on its recent product deliveries for Ontario and Australia
Pathway Health and Canntab Therapeutics strike agreement to provide oral tablet cannabinoid products in select Canadian pharmacies
Canntab Therapeutics receives medical sales license from Health Canada for its Ontario facility
Canntab Therapeutics reaches agreement with 36Eight Technologies to provide effective medical solutions for patients
Canntab Reaches Agreement with Innovative Bioinformatics Company, 36eight Technologies Inc.
Dow pulls to above the flatline after morning struggles as traders digest jobs data
Canntab Therapeutics brings in C$1,259,250 gross from early exercise of warrants
Canntab Announces the Early Exercise of $1,259,250 Warrants
Canntab Therapeutics receives export license from Health Canada
Canntab Receives Export License Approval from Health Canada
Canntab Therapeutics wins Australian patent related to its proprietary cannabidiol formulations
Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia
Canntab Therapeutics says it has completed its second delivery of two additional SKU's ordered by MediPharm Labs
Canntab Engages Independent Trading Group for Market Making Services
Canntab Grants Options
Canntab Granted 2nd Patent For Immediate Release Cannabidiol Formulation Tablets
Canntab Announces Closing of Convertible Debenture Private Placement